Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, announces today that it has filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and financial report, with the Autorité des marchés financiers (the AMF) as well as its Annual Report 2021 (“Form 20-F”) for the financial year ended December 31, 2021 with the “Securities and Exchange Commission” (SEC ) in the USA.
These documents can be consulted on the Company’s website (www.inventivapharma.com), section
“Investors”. In addition, the 2021 Universal Registration Document is available on the AMF website (www.amf-france.org) and the 2021 Annual Report (“Form 20-F”) is also available on the the SEC (www.sec.gov).